ライフサイエンスコーパス: nelarabine

1 ated with nelarabine (42% with v 81% without nelarabine).

2 ay provide a predictive test for response to nelarabine.

3 h T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.

4 xicity for clofarabine and neurotoxicity for nelarabine.

5 rovide a prognostic test for the activity of nelarabine.

6 % for 38 stage two RER patients treated with nelarabine.

7 Nelarabine (1.2 g/m(2)) was infused on days 1, 3, and 5.

8 tropenic infections in patients treated with nelarabine (42% with v 81% without nelarabine).

9 Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-ar

10 armacokinetics of a novel purine nucleoside, nelarabine, a soluble prodrug of 9-beta-D-arabinosylguan

11 t significant adverse events associated with nelarabine administration are neurologic.

12 suggest the need for further exploration of nelarabine against fludarabine-refractory diseases.

13 or 16 stage one RER patients treated without nelarabine and 74% for 38 stage two RER patients treated

14 cified times for the determination of plasma nelarabine and ara-G concentrations.

15 Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular

16 cycle pharmacokinetic data, including plasma nelarabine and araG levels, were obtained on all patient

17 ns for the use of novel therapies, including nelarabine and gamma-secretase inhibitors, in adult pati

18 The pharmacokinetics of nelarabine and/or ara-G were evaluated in 71 patients (2

19 a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patien

20 Nelarabine, as expected from its design, is a drug that

21 , all patients received six 5-day courses of nelarabine at 650 mg/m(2) once per day (10 SER patients

22 icant differences in the pharmacokinetics of nelarabine between any of the groups of patients.

23 New agents such as nelarabine, bortezomib, and clofarabine may be effective

24 Nelarabine (compound 506U78), a water soluble prodrug of

25 For schedule A, patient received nelarabine daily for 5 days, whereas for schedule B, nel

26 odrug of 9-beta-D-arabinosylguanine (ara-G), nelarabine, demonstrated efficacy against T-cell acute l

27 The initial nelarabine dose was 1.2 g/m2 daily for 5 consecutive day

28 to 75 mg/kg and was linearly related to the nelarabine dose.

29 from 11.6 micromol/L to 308.7 micromol/L at nelarabine doses of 5 to 75 mg/kg and was linearly relat

30 The use of nelarabine for relapsed and refractory T-ALL results in

31 We sought to define the response rate of nelarabine in children and young adults with refractory

32 The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minu

33 tility of clofarabine in acute leukemias and nelarabine in T-cell diseases.

34 prodrug of 9-beta-D-arabinosylguanine (araG; Nelarabine), in pediatric and adult patients with refrac

35 mg/m(2)) was administered 4 hours before the nelarabine infusion.

36 of ara-G occurred at or near the end of the nelarabine infusion.

37 Nelarabine is a novel nucleoside with significant cytoto

38 Nelarabine is active as a single agent in recurrent T-ce

39 Nelarabine is an effective prodrug of ara-G, allowing sy

40 Nelarabine is an effective regimen against indolent leuk

41 Fludarabine plus nelarabine is an effective, well-tolerated regimen again

42 For patients with relapsed T-cell ALL, nelarabine is available.

43 Nelarabine is well tolerated and has significant antitum

44 was 73% versus 69% for those treated without nelarabine (n = 16).

45 Five-year EFS for all patients receiving nelarabine (n = 70) was 73% versus 69% for those treated

46 Nelarabine, prodrug of arabinosylguanine (ara-G), has de

47 Both clofarabine and nelarabine recently received an accelerated approval by

48 to evaluate the efficacy of fludarabine with nelarabine (the prodrug of arabinosylguanine [ara-G]) in

49 assess the feasibility and safety of adding nelarabine to a BFM 86-based chemotherapy regimen in chi

50 Addition of nelarabine to a BFM 86-based chemotherapy regimen was we

51 planned to determine whether the addition of nelarabine to front-line therapy for T-cell leukemia in

52 % for 22 stage two SER patients treated with nelarabine versus 69% for 16 stage one RER patients trea

53 Nelarabine was administered daily, as a 1-hour intraveno

54 Nelarabine was administered on an alternate day schedule

55 ne daily for 5 days, whereas for schedule B, nelarabine was administered on days 1, 3, and 5.

56 Clofarabine and nelarabine were designed based on preclinical and clinic